The beneficial local and abscopal effect of splenic irradiation in frail patients with chronic lymphocytic leukaemia

Netherlands Journal of Medicine

Volumn 74, Issue 3, 2016, Pages 122-129

  Aalbers, A M ^a   Aarts, M J ^b   Krol, A D G ^c   Marijnen, C A M ^c   Posthuma, E F M ^a  

^a REINIER DE GRAAF HOSPITAL   (Netherlands)

^b Netherlands Cancer Registry   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Abscopal effect; Chronic lymphocytic leukaemia; Comorbidity; Radiotherapy; Spleen

Indexed keywords

ABDOMINAL DISCOMFORT; ADULT; AGE; AGED; ARTICLE; BONE MARROW BIOPSY; BRAIN INFARCTION; CANCER IMMUNOTHERAPY; CANCER REGISTRY; CHARLSON COMORBIDITY INDEX; CHROMOSOME ANALYSIS; CHRONIC LYMPHATIC LEUKEMIA; COMORBIDITY; DEATH; DYSPNEA; FATIGUE; FEMALE; HEMATOLOGIC DISEASE; HUMAN; HUMAN TISSUE; IRRADIATION; LEUKOCYTOSIS; LYMPHADENOPATHY; LYMPHOCYTOMA; MALE; NIGHT SWEAT; PREVALENCE; RADIATION DOSE; SPLENIC IRRADIATION; SPLENOMEGALY; VERY ELDERLY; WEIGHT REDUCTION; FOLLOW UP; FRAIL ELDERLY; INCIDENCE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MIDDLE AGED; NETHERLANDS; RADIATION RESPONSE; RETROSPECTIVE STUDY; SPLEEN; SURVIVAL RATE; TREATMENT OUTCOME; TRENDS;

ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; FRAIL ELDERLY; HUMANS; INCIDENCE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NETHERLANDS; RETROSPECTIVE STUDIES; SPLEEN; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84962033778     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Surveillance, Epidemiology, and End Results Program. National Cancer Institute, 2015. http://seer.cancer.gov
2. Thurmes P, Call T, Slager S, et al. Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2008;49:49-56.
3. Goede V, Cramer P, Busch R, et al. Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials. Haematologica. 2014;99:1095-100.
4. Satram-Hoang S, Reyes C, Hoang KQ, Momin F, Skettino S. Treatment practice in the elderly patient with chronic lymphocytic leukemiaanalysis of the combined SEER and Medicare database. Ann Hematol. 2014;93:1335-44.
5. Eichhorst B, Dreyling M, Robak T, Montserrat E, Hallek M, Group EGW. Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22:vi50-4.
6. Kater AP, Wittebol S, Chamuleau ME, van Gelder M, van Oers MH, Hovon CCL Working Party. Dutch guidelines for diagnosis and treatment of chronic lymphocytic leukaemia 2011. Neth J Med. 2011;69:422-29.
7. Woyach JA, Ruppert AS, Rai K, et al. Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies. J Clin Oncol. 2013;31:440-7.
8. Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2010;28:1749-55.
9. Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371:213-23.
10. Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370:997-1007.
11. Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370:1101-10.
12. Weinmann M, Becker G, Einsele H, Bamberg M. Clinical indications and biological mechanisms of splenic irradiation in autoimmune diseases. Strahlenther Onkol. 2001;177:105-11.
13. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446-56.
14. Paule B, Cosset JM, Le Bourgeois JP. The possible role of radiotherapy in chronic lymphocytic leukaemia: a critical review. Radiother Oncol. 1985;4:45-54.
15. Byhardt RW, Brace KC, Wiernik PH. The role of splenic irradiation in chronic lymphocytic leukemia. Cancer. 1975;35:1621-5.
16. Aabo K, Walbom-Jorgensen S. Spleen irradiation in chronic lymphocytic leukemia (CLL): palliation in patients unfit for splenectomy. Am J Hematol. 1985;19:177-80.
17. Singh AK, Bates T, Wetherley-Mein G. A preliminary study of low-dose splenic irradiation for the treatment of chronic lymphocytic and prolymphocytic leukaemias. Scand J Haematol. 1986;37:50-8.
18. Roncadin M, Arcicasa M, Trovo MG, et al. Splenic irradiation in chronic lymphocytic leukemia. A 10-year experience at a single institution. Cancer. 1987;60:2624-8.
19. Chisesi T, Capnist G, Dal Fior S. Splenic irradiation in chronic lymphocytic leukemia. Eur J Haematol. 1991;46:202-4.
20. Van Mook WN, Fickers MM, Verschueren TA. Clinical and immunological evaluation of primary splenic irradiation in chronic lymphocytic leukemia: a study of 24 cases. Ann Hematol. 2001;80:216-23.
21. Catovsky D, Richards S, Fooks J, Hamblin TJ. CLL trials in the United Kingdom. The Medical Research Council CLL Trials 1, 2 and 3. Leuk Lymphoma. 1991;Supplement:105-112.
22. Thomson AE, Vaughan-Smith S, Peel WE, Wetherley-Mein G. The intrinsic radiosensitivity of lymphocytes in chronic lymphocytic leukaemia, quantitatively determined independently of cell death rate factors. Int J Radiat Biol Relat Stud Phys Chem Med. 1985;48:943-61.
23. Terstappen LW, de Grooth BG, van Berkel W, ten Napel CH, van Reijn M, Greve J. The effects of splenic irradiation on lymphocyte subpopulations in chronic B-lymphocytic leukemia. Eur J Haematol. 1988;41:496-505.
24. Mole RH. Whole body irradiation; radiobiology or medicine? Br J Radiol. 1953;26:234-41.
25. Bessler H, Bergman M, Salman H, Cohen AM, Fenig E, Djaldetti M. Factor(s) released from irradiated B-CLL cells induce apoptosis in leukemic lymphocytes. Cancer Lett. 2002;179:103-8.
26. Ten Hacken E, Burger JA. Molecular pathways: targeting the microenvironment in chronic lymphocytic leukemia--focus on the B-cell receptor. Clin Cancer Res. 2014;20:548-56.
27. Lavrenkov K, Krepel-Volsky S, Levi I, Ariad S. Low dose palliative radiotherapy for splenomegaly in hematologic disorders. Leuk Lymphoma. 2012;53:430-4.
28. McClanahan F, Hanna B, Miller S, et al. PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia. Blood. 2015;126:203-11.
29. Twyman-Saint Victor C, Rech AJ, Maity A, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520:373-7.